Anti-hypertensives, Anti-dyslipidemics and Cardiac Therapy

According to IMS MIDAS data, global sales of cardiovascular and antithrombotic drugs, i.e. anti-hypertensives, anti-dyslipidemics, antithrombotics and cardiac therapies, reached $72.6bn in 2002. However, competition within each of the four therapy areas is fierce, with many leading brands facing the threat of generic competition and other key patents due to expire over the next five years 

Scope

Provide a reference tool for the cardiovascular market, including an overview of the anti-hypertensives, anti-dyslipidemics and cardiac therapies 

Detail sales trends from 2001 to 2002 by therapy area, by class and by top 10 brands 

Summarize the key events in the market in the first half 2003 and analyze the impact of these events on the future dynamics of the market 

Identify the key late stage developmental compounds that have the potential to achieve blockbuster status within their respective therapy areas 

Report Highlights

Growth in the anti-hypertensives market is principally driven by sales of the ARBs, which continue to benefit from patent protection. Sales of the ARBs have increased following the expansion of the ACE-intolerant population (due to an increase in prescribing of ACE inhibitors) and positive trial results for major brands in additional indications 

Statins continue to lead the anti-dyslipidemic market, although generic competition is becoming more aggressive. In the future, the use of combination therapy within the anti-dyslipidemic market is expected to increase considerably as novel adjuncts, such as Zetia (ezetimibe), gain greater acceptance within the market 

Although generating the smallest revenue, cardiac therapy offers the greatest potential for new agents due to the substantial patient populations and high unmet need. Therefore, new products such as Natrecor (nesiritide) and Ranexa (ranolazine) may inject new dynamism into this “stagnant” market 

Reasons to Purchase

Gain an overview of the dynamics of the anti-hypertensive, anti-dyslipidemic and cardiac therapy markets in 2003 

Understand the key events impacting the future dynamics of these key cardiovascular therapy areas and the leading brands within each area 

Recognize the threats facing the leading products and identify key opportunities for R&D  

Publisher: Datamonitor Cardiovascular Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Cardiovascular.html#a7